RPIA

Ribose-5-phosphate isomerase · P49247 · RPIA on Sugi Atlas →

0 patent compounds predicted against RPIA, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RPIA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Role of Genetic Factors in the Development of Lung Disease nanRECRUITING
InsightRP2 Registry nanRECRUITING
Biomarkers in Retinitis Pigmentosa nanUNKNOWN
Natural History Study of Retinitis Pigmentosa Type 11 nanACTIVE_NOT_RECRUITING
Return of Actionable Variants Empirical Study nanCOMPLETED
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa nanCOMPLETED
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing nanRECRUITING
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RPIA binder may also engage these)

ProteinNameSimilarity
A2TLM1 0.984 A2TLM1 →
P47968 0.982 P47968 →
Q3T186 0.972 Q3T186 →
D2XV59 0.946 D2XV59 →
Q58DC5 0.945 Q58DC5 →
Q5R5F8 0.942 Q5R5F8 →
ACACA Acetyl-CoA carboxylase 1 0.942 landscape →
P11497 0.942 P11497 →
P11029 0.942 P11029 →
Q28559 0.941 Q28559 →
Q5SWU9 0.941 Q5SWU9 →
Q4R4U1 0.941 Q4R4U1 →
O08582 0.941 O08582 →
Q96RR1 0.940 Q96RR1 →
Q9TTS3 0.940 Q9TTS3 →
O00178 0.940 O00178 →
Q5XGS8 0.940 Q5XGS8 →
F1N9S8 0.940 F1N9S8 →
Q9NVE7 0.939 Q9NVE7 →
Q28ET8 0.939 Q28ET8 →
Q5RHX6 0.939 Q5RHX6 →
Q6DC64 0.938 Q6DC64 →
B9N1F9 0.938 B9N1F9 →
DCUN1D4 DCN1-like protein 4 0.938 landscape →
Q80YV4 0.937 Q80YV4 →
Q923S8 0.937 Q923S8 →
Q5R8Q7 0.937 Q5R8Q7 →
Q8R4N0 0.937 Q8R4N0 →
Q3ZBL5 0.937 Q3ZBL5 →
Q8L5Y9 0.936 Q8L5Y9 →